Lake Street Keeps Their Buy Rating on MiMedx Group (MDXG)
Lake Street analyst Frank Takkinen maintained a Buy rating on MiMedx Group today and set a price target of $12.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Takkinen covers the Healthcare sector, focusing on stocks such as Sight Sciences, ClearPoint Neuro, and Hyperfine. According to TipRanks, Takkinen has an average return of -0.6% and a 40.00% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MiMedx Group with a $12.00 average price target.
Based on MiMedx Group’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $113.73 million and a net profit of $16.75 million. In comparison, last year the company earned a revenue of $84.06 million and had a net profit of $8.1 million
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MDXG in relation to earlier this year. Earlier this month, Kimberly Maersk-Moller, the CCO of MDXG sold 58,300.00 shares for a total of $432,003.00.
Read More on MDXG:
